Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment

European Journal of Pharmacology

Volumn 718, Issue 1-3, 2013, Pages 502-523

  De Bartolomeis, Andrea ^a   Avvisati, Livia ^a   Iasevoli, Felice ^a   Tomasetti, Carmine ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antidepressant; Benzodiazepine; Bipolar disorder; Mood stabilizer; Postsynaptic density; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUOXETINE; FLUVOXAMINE; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; LITHIUM; LORAZEPAM; MIRTAZAPINE; MITOGEN ACTIVATED PROTEIN KINASE; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROTROPHIC FACTOR; OLANZAPINE; PROTEIN KINASE B; QUETIAPINE; RISPERIDONE; RITANSERIN; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MANIA; MENTAL DISEASE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANTIDEPRESSANT; BENZODIAZEPINE; BIPOLAR DISORDER; MOOD STABILIZER; POSTSYNAPTIC DENSITY; SCHIZOPHRENIA;

AFFECT; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG COMBINATIONS; HUMANS; INTRACELLULAR SPACE; MENTAL DISORDERS;

EID: 84887108872     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.034     Document Type: Review

References (278)

1. S.H. Abbasi, H. Behpournia, A. Ghoreshi, B. Salehi, M. Raznahan, S.A. Rezazadeh, F. Rezaei, and S. Akhondzadeh The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial Schizophr. Res. 116 2010 101 106
2. H.M. Abelaira, G.Z. Reus, K.F. Ribeiro, G. Zappellini, G.K. Ferreira, L.M. Gomes, M. Carvalho-Silva, T.F. Luciano, S.O. Marques, E.L. Streck, C.T. Souza, and J. Quevedo Effects of acute and chronic treatment elicited by lamotrigine on behavior, energy metabolism, neurotrophins and signaling cascades in rats Neurochem. Int. 59 2011 1163 1174
3. Y. Ago, S. Nakamura, A. Baba, and T. Matsuda Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 30 2005 43 51 (Pubitemid 40024398)
4. F.R. Agostinho, G.Z. Reus, R.B. Stringari, K.F. Ribeiro, A.K. Ferraro, J. Benedet, N. Rochi, G. Scaini, E.L. Streck, and J. Quevedo Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain Neurosci. Lett. 487 2011 278 281
5. F.R. Agostinho, G. Scaini, G.K. Ferreira, I.C. Jeremias, G.Z. Reus, G.T. Rezin, A.A. Castro, A.I. Zugno, J. Quevedo, and E.L. Streck Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain Brain Res. Bull. 80 2009 337 340
6. M.R. Ahmed, V.V. Gurevich, K.N. Dalby, J.L. Benovic, and E.V. Gurevich Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation J. Pharmacol. Exp. Ther. 325 2008 276 283 (Pubitemid 351439182)
7. S. Akhondzadeh, M. Malek-Hosseini, A. Ghoreishi, M. Raznahan, and S.A. Rezazadeh Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study Prog. Neuro-psychopharmacol. Biol. Psychiatry 32 2008 1879 1883
8. J. Alexander, P. Tharyan, C. Adams, T. John, C. Mol, and J. Philip Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine Br. J. Psychiatry 185 2004 63 69 (Pubitemid 38951631)
9. H. Alimohamad, N. Rajakumar, Y.H. Seah, and W. Rushlow Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum Biol. Psychiatry 57 2005 533 542 (Pubitemid 40311989)
10. J. Almeida, E.M. Serrao, A.T. Almeida, and J.G. Afonso Effective treatment with clozapine and valproate for refractory schizophrenia-like psychosis after cerebellar hemorrhage Clin. Neuropharmacol. 34 2011 131 132
11. A. Ambesi-Impiombato, F. Panariello, C. Dell'aversano, C. Tomasetti, G. Muscettola, and A. de Bartolomeis Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain Synapse 61 2007 429 439 (Pubitemid 46559540)
12. F. Angelucci, L. Aloe, P. Jimenez-Vasquez, and A.A. Mathe Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression Int. J. Neuropsychopharmacol. 6 2003 225 231 (Pubitemid 37248000)
13. H.J. Assion, H. Reinbold, S. Lemanski, M. Basilowski, and G. Juckel Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial Pharmacopsychiatry 41 2008 24 28 (Pubitemid 351195889)
14. J.M. Aubry, M. Schwald, E. Ballmann, and F. Karege Early effects of mood stabilizers on the Akt/GSK-3beta signaling pathway and on cell survival and proliferation Psychopharmacology 205 2009 419 429
15. O. Bai, J. Chlan-Fourney, R. Bowen, D. Keegan, and X.M. Li Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs J. Neurosci. Res. 71 2003 127 131 (Pubitemid 36008409)
16. R.W. Baker, E. Brown, H.S. Akiskal, J.R. Calabrese, T.A. Ketter, L.M. Schuh, P.T. Trzepacz, J.G. Watkin, and M. Tohen Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania Br. J. Psychiatry 185 2004 472 478 (Pubitemid 39643282)
17. V.P. Bakshi, and M.A. Geyer Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine Psychopharmacology 122 1995 198 201 (Pubitemid 26019155)
18. V.P. Bakshi, N.R. Swerdlow, and M.A. Geyer Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response J. Pharmacol. Exp. Ther. 271 1994 787 794 (Pubitemid 24377766)
19. C. Barbui, S. Accordini, M. Nose, S. Stroup, M. Purgato, F. Girlanda, E. Esposito, A. Veronese, M. Tansella, and A. Cipriani Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial J. Clin. Psychopharmacol. 31 2011 266 273
20. T.R. Barnes, and C. Paton Antipsychotic polypharmacy in schizophrenia: benefits and risks CNS Drugs 25 2011 383 399
21. J. Battaglia, S. Moss, J. Rush, J. Kang, R. Mendoza, L. Leedom, W. Dubin, C. McGlynn, and L. Goodman Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study Am. J. Emerg. Med. 15 1997 335 340 (Pubitemid 27284198)
22. J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron Akt/GSK3 signaling in the action of psychotropic drugs Annu. Rev. Pharmacol. Toxicol. 49 2009 327 347
23. J.M. Beaulieu, S. Marion, R.M. Rodriguiz, I.O. Medvedev, T.D. Sotnikova, V. Ghisi, W.C. Wetsel, R.J. Lefkowitz, R.R. Gainetdinov, and M.G. Caron A beta-arrestin 2 signaling complex mediates lithium action on behavior Cell 132 2008 125 136
24. J.M. Beaulieu, T.D. Sotnikova, W.D. Yao, L. Kockeritz, J.R. Woodgett, R.R. Gainetdinov, and M.G. Caron Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade Proc. Natl. Acad. Sci. USA 101 2004 5099 5104 (Pubitemid 38469209)
25. S. Bender, T. Linka, J. Wolstein, S. Gehendges, H.J. Paulus, U. Schall, and M. Gastpar Safety and efficacy of combined clozapine-lithium pharmacotherapy Int. J. Neuropsychopharmacol. 7 2004 59 63 (Pubitemid 38523808)
26. M. Berk, C. Ichim, and S. Brook Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study Int. Clin. Psychopharmacol. 16 2001 87 92 (Pubitemid 32171833)
27. S.A. Bieniek, R.L. Ownby, A. Penalver, and R.A. Dominguez A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation Pharmacotherapy 18 1998 57 62 (Pubitemid 28059004)
28. S. Bo, A. Abu-Akel, M. Kongerslev, U.H. Haahr, and E. Simonsen Risk factors for violence among patients with schizophrenia Clin. Psychol. Rev. 31 2011 711 726
29. S. Bo, A. Forth, M. Kongerslev, U.H. Haahr, L. Pedersen, and E. Simonsen Subtypes of aggression in patients with schizophrenia: the role of personality disorders Crim. Behav. Ment. Health 23 2013 124 137
30. C.L. Bowden, E. Vieta, K.S. Ice, J.H. Schwartz, P.P. Wang, and M. Versavel Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial J. Clin. Psychiatry 71 2010 130 137
31. N.J. Brandon, P. Delmas, J.T. Kittler, B.J. McDonald, W. Sieghart, D.A. Brown, T.G. Smart, and S.J. Moss GABAA receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway J. Biol. Chem. 275 2000 38856 38862 (Pubitemid 32009223)
32. K. Broadbelt, and L.B. Jones Evidence of altered calmodulin immunoreactivity in areas 9 and 32 of schizophrenic prefrontal cortex J. Psychiatr. Res. 42 2008 612 621
33. J.L. Browning, T. Patel, P.C. Brandt, K.A. Young, L.A. Holcomb, and P.B. Hicks Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions Biol. Psychiatry 57 2005 617 623 (Pubitemid 40409701)
34. R.W. Buchanan, B. Kirkpatrick, N. Bryant, P. Ball, and A. Breier Fluoxetine augmentation of clozapine treatment in patients with schizophrenia Am. J. Psychiatry 153 1996 1625 1627 (Pubitemid 26406176)
35. P.F. Buckley, and S.M. Stahl Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr. Scand. 115 2007 93 100 (Pubitemid 46114869)
36. F.P. Bymaster, D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman, and D.T. Wong Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 14 1996 87 96 (Pubitemid 26053226)
37. D.E. Casey, D.G. Daniel, C. Tamminga, J.M. Kane, T. Tran-Johnson, P. Wozniak, W. Abi-Saab, J. Baker, L. Redden, N. Greco, and M. Saltarelli Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 34 2009 1330 1338
38. D.E. Casey, D.G. Daniel, A.A. Wassef, K.A. Tracy, P. Wozniak, and K.W. Sommerville Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 28 2003 182 192
39. M.A. Casu, A. Sanna, G.P. Spada, M. Falzoi, R. Mongeau, and L. Pani Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus accumbens Brain Res. 1141 2007 15 24 (Pubitemid 46394502)
40. B. Chen, J.F. Wang, B.C. Hill, and L.T. Young Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos Brain Res. Mol. Brain Res. 70 1999 45 53 (Pubitemid 29278606)
41. G. Chen, L.D. Huang, Y.M. Jiang, and H.K. Manji The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3 J. Neurochem. 72 1999 1327 1330 (Pubitemid 29085050)
42. G. Chen, and H.K. Manji The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers Curr. Opin. Psychiatry 19 2006 313 323 (Pubitemid 44309491)
43. J. Chen, K. Gao, and D.E. Kemp Second-generation antipsychotics in major depressive disorder: update and clinical perspective Curr. Opin. Psychiatry 24 2011 10 17
44. P.S. Chen, G.S. Peng, G. Li, S. Yang, X. Wu, C.C. Wang, B. Wilson, R.B. Lu, P.W. Gean, D.M. Chuang, and J.S. Hong Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes Mol. Psychiatry 11 2006 1116 1125 (Pubitemid 44867481)
45. Z. Chen, H. Xu, S. Haimano, X. Li, and X.M. Li Quetiapine and venlafaxine synergically regulate heme oxygenase-2 protein expression in the hippocampus of stressed rats Neurosci. Lett. 389 2005 173 177 (Pubitemid 41267221)
46. Y. Chertkow, O. Weinreb, M.B. Youdim, and H. Silver The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex Int. J. Neuropsychopharmacol. 9 2006 287 296 (Pubitemid 43780496)
47. Y. Chertkow, O. Weinreb, M.B. Youdim, and H. Silver Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment J. Neural Transm. 114 2007 1443 1454 (Pubitemid 350112279)
48. Y. Chertkow, O. Weinreb, M.B. Youdim, and H. Silver Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine Prog. Neuro-psychopharmacol. Biol. Psychiatry 31 2007 1356 1362 (Pubitemid 47302546)
49. Y. Chertkow, O. Weinreb, M.B. Youdim, and H. Silver Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia J. Neural Transm. 116 2009 1529 1541
50. J. Chlan-Fourney, P. Ashe, K. Nylen, A.V. Juorio, and X.M. Li Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration Brain Res. 954 2002 11 20 (Pubitemid 35223437)
51. P. Chue, R. Welch, and M. Snaterse Combination risperidone and quetiapine therapy in refractory schizophrenia Can. J. Psychiatry 46 2001 86 87 (Pubitemid 32209351)
52. L.E. Collins-Praino, S.J. Podurgiel, R. Kovner, P.A. Randall, and J.D. Salamone Extracellular GABA in globus pallidus increases during the induction of oral tremor by haloperidol but not by muscarinic receptor stimulation Behav. Brain Res. 234 2012 129 135
53. S.A. Corya, S.W. Andersen, H.C. Detke, L.S. Kelly, L.E. Van Campen, T.M. Sanger, D.J. Williamson, and S. Dube Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study J. Clin. Psychiatry 64 2003 1349 1356 (Pubitemid 37490241)
54. E. Costa, J.M. Davis, E. Dong, D.R. Grayson, A. Guidotti, L. Tremolizzo, and M. Veldic A GABAergic cortical deficit dominates schizophrenia pathophysiology Crit. Rev. Neurobiol. 16 2004 1 23 (Pubitemid 39586898)
55. T.I. Cremers, K. Rea, F.J. Bosker, H.V. Wikstrom, S. Hogg, A. Mork, and B.H. Westerink Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 32 2007 1550 1557 (Pubitemid 46920163)
56. A. Czubak, E. Nowakowska, K. Kus, K. Burda, J. Metelska, W. Baer-Dubowska, and M. Cichocki Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF) Pharmacol. Rep. 61 2009 1017 1023
57. L. Danovich, O. Weinreb, M.B. Youdim, and H. Silver The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment Int. J. Neuropsychopharmacol. 14 2011 143 155
58. A. de Bartolomeis, E.F. Buonaguro, and F. Iasevoli Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins Psychopharmacology 225 2013 1 19
59. A. de Bartolomeis, C. Sarappa, S. Magara, and F. Iasevoli Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia Eur. J. Pharmacol. 682 2012 1 11
60. A. de Bartolomeis, C. Tomasetti, M. Cicale, P.X. Yuan, and H.K. Manji Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 22 2012 527 535
61. A. de Bartolomeis, and C. Tomasetti Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins Mol. Neurobiol. 46 2012 275 296
62. J. de Leon, V. Santoro, C. D'Arrigo, and E. Spina Interactions between antiepileptics and second-generation antipsychotics Expert Opin. Drug Metab. Toxicol. 8 2012 311 334
63. P. De Sarno, X. Li, and R.S. Jope Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium Neuropharmacology 43 2002 1158 1164 (Pubitemid 36009369)
64. P. Decina, S. Mukherjee, V. Bocola, F. Saraceni, C. Hadjichristos, and P. Scapicchio Adjunctive trazodone in the treatment of negative symptoms of schizophrenia Hosp. Community Psychiatry 45 1994 1220 1223 (Pubitemid 24375295)
65. M.P. Delbello, M.L. Schwiers, H.L. Rosenberg, and S.M. Strakowski A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania J. Am. Acad. Child Adolesc. Psychiatry 41 2002 1216 1223 (Pubitemid 38338041)
66. C. Dell'aversano, C. Tomasetti, F. Iasevoli, and A. de Bartolomeis Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders Brain Res. Bull. 79 2009 123 129
67. D. Denys, A.A. Klompmakers, and H.G. Westenberg Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine Psychopharmacology 176 2004 195 203 (Pubitemid 39517949)
68. E. Di Daniel, A.W. Mudge, and P.R. Maycox Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons Bipolar Disord. 7 2005 33 41 (Pubitemid 40227834)
69. M. Dold, C. Li, M. Tardy, V. Khorsand, D. Gillies, and S. Leucht Benzodiazepines for schizophrenia Cochrane Database Syst. Rev. 11 2012 CD006391
70. E. Dong, R.C. Agis-Balboa, M.V. Simonini, D.R. Grayson, E. Costa, and A. Guidotti Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia Proc. Natl. Acad. Sci. USA 102 2005 12578 12583 (Pubitemid 41266401)
71. E. Dong, M. Nelson, D.R. Grayson, E. Costa, and A. Guidotti Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation Proc. Natl. Acad. Sci. USA 105 2008 13614 13619
72. W.C. Drevets Neuroimaging studies of mood disorders Biol. Psychiatry 48 2000 813 829
73. R.S. Duman, and B. Voleti Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents Trends Neurosci. 35 2012 47 56
74. H. Einat, P. Yuan, T.D. Gould, J. Li, J. Du, L. Zhang, H.K. Manji, and G. Chen The role of the extracellular signal-regulated kinase signaling pathway in mood modulation J. Neurosci. 23 2003 7311 7316 (Pubitemid 36999520)
75. S.R. Engel, T.K. Creson, Y. Hao, Y. Shen, S. Maeng, T. Nekrasova, G.E. Landreth, H.K. Manji, and G. Chen The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement Mol. Psychiatry 14 2009 448 461
76. S. Englisch, F. Enning, M. Grosshans, L. Marquardt, R. Waltereit, and M. Zink Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapine monotherapy Clin. Neuropharmacol. 33 2010 227 229
77. S. Englisch, and M. Zink Treatment-resistant schizophrenia: evidence-based strategies Mens Sana Monogr. 10 2012 20 32
78. A. Fagiolini, M. Nitti, R.N. Forgione, F.S. Marra, and F. Casamassima Aripiprazole for the treatment of bipolar disorder: a review of current evidence Expert Opin. Pharmacother. 12 2011 473 488
79. A. Farahani, and C.U. Correll Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment J. Clin. Psychiatry 73 2012 486 496
80. D. Farnbach-Pralong, R. Bradbury, D. Copolov, and B. Dean Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors Eur. J. Pharmacol. 349 1998 R7 8
81. S. Fazel, G. Gulati, L. Linsell, J.R. Geddes, and M. Grann Schizophrenia and violence: systematic review and meta-analysis PLoS Med. 6 2009 e1000120
82. W.W. Fleischhacker, M.E. Heikkinen, J.P. Olie, W. Landsberg, P. Dewaele, R.D. McQuade, J.Y. Loze, D. Hennicken, and W. Kerselaers Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial Int. J. Neuropsychopharmacol. 13 2010 1115 1125
83. J. Flores-Hernandez, C. Cepeda, E. Hernandez-Echeagaray, C.R. Calvert, E.S. Jokel, A.A. Fienberg, P. Greengard, and M.S. Levine Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32 J. Neurophysiol. 88 2002 3010 3020 (Pubitemid 35448687)
84. J. Flores-Hernandez, S. Hernandez, G.L. Snyder, Z. Yan, A.A. Fienberg, S.J. Moss, P. Greengard, and D.J. Surmeier D(1) dopamine receptor activation reduces GABA(A) receptor currents in neostriatal neurons through a PKA/DARPP-32/PP1 signaling cascade J. Neurophysiol. 83 2000 2996 3004 (Pubitemid 30321488)
85. K.N. Fountoulakis, E. Vieta, M. Siamouli, M. Valenti, S. Magiria, T. Oral, D. Fresno, P. Giannakopoulos, and G.S. Kaprinis Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder Ann. Gen. Psychiatry 6 2007 27
86. O. Freudenreich, and D.C. Goff Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations Acta Psychiatr. Scand. 106 2002 323 330 (Pubitemid 35176874)
87. O. Freudenreich, D.C. Henderson, J.P. Walsh, M.A. Culhane, and D.C. Goff Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial Schizophr. Res. 92 2007 90 94 (Pubitemid 46561216)
88. B.N. Frey, S.S. Valvassori, G.Z. Reus, M.R. Martins, F.C. Petronilho, K. Bardini, F. Dal-Pizzol, F. Kapczinski, and J. Quevedo Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania J. Psychiatry Neurosci. 31 2006 326 332 (Pubitemid 44497429)
89. T. Fukumoto, S. Morinobu, Y. Okamoto, A. Kagaya, and S. Yamawaki Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain Psychopharmacology 158 2001 100 106
90. F. Fumagalli, A. Frasca, M. Sparta, F. Drago, G. Racagni, and M.A. Riva Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex Mol. Pharmacol. 69 2006 1366 1372
91. K. Gao, P. Gajwani, O. Elhaj, and J.R. Calabrese Typical and atypical antipsychotics in bipolar depression J. Clin. Psychiatry 66 2005 1376 1385 (Pubitemid 41779535)
92. D. Gillies, S. Sampson, A. Beck, and J. Rathbone Benzodiazepines for psychosis-induced aggression or agitation Cochrane Database Syst. Rev. 4 2013 CD003079
93. T.P. Gilmer, C.R. Dolder, D.P. Folsom, W. Mastin, and D.V. Jeste Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004 Psychiatr. Serv. 58 2007 1007 1010 (Pubitemid 47122882)
94. M. Gitlin, and M.A. Frye Maintenance therapies in bipolar disorders Bipolar Disord. 14 Suppl 2 2012 51 65
95. G. Gobbi, P.O. Gaudreau, and N. Leblanc Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis J. Clin. Psychopharmacol. 26 2006 467 473 (Pubitemid 44401465)
96. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am. J. Psychiatry 158 2001 1367 1377 (Pubitemid 32847232)
97. D.C. Goff, K.K. Midha, O. Sarid-Segal, J.W. Hubbard, and E. Amico A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia Psychopharmacology 117 1995 417 423
98. P.S. Goldman-Rakic The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive Philos. Trans. R. Soc. Lond. B Biol. Sci. 351 1996 1445 1453 (Pubitemid 27005371)
99. G. Goodwin, W. Fleischhacker, C. Arango, P. Baumann, M. Davidson, M. de Hert, P. Falkai, S. Kapur, S. Leucht, R. Licht, D. Naber, V. O'Keane, G. Papakostas, E. Vieta, and J. Zohar Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 19 2009 520 532
100. C.A. Grimes, and R.S. Jope CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium J. Neurochem. 78 2001 1219 1232 (Pubitemid 32899754)
101. H. Grunze, E. Vieta, G.M. Goodwin, C. Bowden, R.W. Licht, H.J. Moller, and S. Kasper The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry 10 2009 85 116
102. H. Grunze, E. Vieta, G.M. Goodwin, C. Bowden, R.W. Licht, H.J. Moller, and S. Kasper The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry 14 2013 154 219
103. A. Guidotti, J. Auta, Y. Chen, J.M. Davis, E. Dong, D.P. Gavin, D.R. Grayson, F. Matrisciano, G. Pinna, R. Satta, R.P. Sharma, L. Tremolizzo, and P. Tueting Epigenetic GABAergic targets in schizophrenia and bipolar disorder Neuropharmacology 60 2011 1007 1016
104. X. Guitart, and E.J. Nestler Chronic administration of lithium or other antidepressants increases levels of DARPP-32 in rat frontal cortex J. Neurochem. 59 1992 1164 1167
105. Y. Hao, T. Creson, L. Zhang, P. Li, F. Du, P. Yuan, T.D. Gould, H.K. Manji, and G. Chen Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis J. Neurosci. 24 2004 6590 6599 (Pubitemid 38971708)
106. A. Hasan, P. Falkai, T. Wobrock, J. Lieberman, B. Glenthoj, W.F. Gattaz, F. Thibaut, and H.J. Moller World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry 14 2013 2 44
107. C. Haw, and J. Stubbs Benzodiazepines - a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital J. Psychopharmacol. 21 2007 645 649 (Pubitemid 47472729)
108. T. Hayashi, N. Yokota, T. Takahashi, Y. Tawara, T. Nishikawa, T. Yano, M. Furutani, T. Fujikawa, J. Horiguchi, and S. Yamawaki Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study Int. Clin. Psychopharmacol. 12 1997 199 205 (Pubitemid 27414633)
109. D.C. Henderson, L. Kunkel, D.D. Nguyen, C.P. Borba, T.B. Daley, P.M. Louie, O. Freudenreich, C. Cather, A.E. Evins, and D.C. Goff An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia Acta Psychiatr. Scand. 113 2006 142 147 (Pubitemid 43340908)
110. C. Hiemke, A. Peled, M. Jabarin, J. Hadjez, H. Weigmann, S. Hartter, I. Modai, M. Ritsner, and H. Silver Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects J. Clin. Psychopharmacol. 22 2002 502 506
111. Hiemke, C., Pfuhlmann, B., 2012. Interactions and monitoring of antipsychotic drugs. In: Handbook of Experimental Pharmacology, pp. 241-265.
112. R.E. Hodgson, and S. Mendis Lithium enabling use of clozapine in a patient with pre-existing neutropenia Br. J. Hosp. Med. (Lond.) 71 2010 535
113. Z.S. Hoffer, R.L. Roth, and M. Mathews Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia Psychosomatics 50 2009 317 324
114. W.G. Honer, A.E. Thornton, E.Y. Chen, R.C. Chan, J.O. Wong, A. Bergmann, P. Falkai, E. Pomarol-Clotet, P.J. McKenna, E. Stip, R. Williams, G.W. MacEwan, K. Wasan, and R. Procyshyn Clozapine alone versus clozapine and risperidone with refractory schizophrenia N. Engl. J. Med. 354 2006 472 482 (Pubitemid 43200298)
115. J.M. Horowitz, A. Goyal, N. Ramdeen, B.H. Hallas, A.T. Horowitz, and G. Torres Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis Synapse 50 2003 353 364 (Pubitemid 37420590)
116. N. Hovelso, T.N. Sager, and A. Mork Combination of escitalopram and a 5-HT((1)A) receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT((2)C) receptor stimulation; suggestive of antipsychotic potential Pharmacol. Biochem. Behav. 97 2011 479 485
117. J.E. Hovens, P.J. Dries, C.T. Melman, R.J. Wapenaar, and A.J. Loonen Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study J. Psychopharmacol. 19 2005 51 57
118. H.S. Huang, A. Matevossian, C. Whittle, S.Y. Kim, A. Schumacher, S.P. Baker, and S. Akbarian Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters J. Neurosci. 27 2007 11254 11262 (Pubitemid 47621326)
119. M. Huang, J. Ichiwaka, Z. Li, J. Dai, and H.Y. Meltzer Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex Psychopharmacology 185 2006 274 281
120. M. Huang, Z. Li, J. Ichikawa, J. Dai, and H.Y. Meltzer Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex Brain Res. 1099 2006 44 55 (Pubitemid 44080087)
121. F. Iasevoli, A. Ambesi-Impiombato, G. Fiore, F. Panariello, G. Muscettola, and A. de Bartolomeis Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes J. Psychopharmacol. 25 2011 875 887
122. F. Iasevoli, G. Fiore, M. Cicale, G. Muscettola, and A. de Bartolomeis Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions Psychiatry Res. 177 2010 255 260
123. F. Iasevoli, G. Latte, L. Avvisati, C. Sarappa, L. Aloj, and A. de Bartolomeis The expression of genes involved in glucose metabolism is affected by N-methyl-d-aspartate receptor antagonism: a putative link between metabolism and an animal model of psychosis J. Neurosci. Res. 90 2012 1756 1767
124. F. Iasevoli, C. Tomasetti, and A. de Bartolomeis Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases Neurochem. Res. 38 2013 1 22
125. F. Iasevoli, C. Tomasetti, F. Marmo, D. Bravi, J. Arnt, and A. de Bartolomeis Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole Psychopharmacology 212 2010 329 344
126. J. Ichikawa, J. Dai, and H.Y. Meltzer Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: role of 5-HT(1A) receptor agonism Brain Res. 1049 2005 182 190 (Pubitemid 41072934)
127. J. Ichikawa, H. Ishii, S. Bonaccorso, W.L. Fowler, I.A. O'Laughlin, and H.Y. Meltzer 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J. Neurochem. 76 2001 1521 1531 (Pubitemid 32198256)
128. D. Ishii, D. Matsuzawa, N. Kanahara, S. Matsuda, C. Sutoh, H. Ohtsuka, K. Nakazawa, M. Kohno, K. Hashimoto, M. Iyo, and E. Shimizu Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway Neurosci. Lett. 471 2010 53 57
129. G. Joffe, V. Terevnikov, M. Joffe, J.H. Stenberg, M. Burkin, and J.
130. R.M. Jones, C. Thompson, and I. Bitter A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania Eur. Psychiatry 21 2006 1 9 (Pubitemid 43243047)
131. R.C. Josiassen, A. Joseph, E. Kohegyi, S. Stokes, M. Dadvand, W.W. Paing, and R.A. Shaughnessy Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial Am. J. Psychiatry 162 2005 130 136 (Pubitemid 40095682)
132. J.M. Kane, C.U. Correll, D.C. Goff, B. Kirkpatrick, S.R. Marder, E. Vester-Blokland, W. Sun, W.H. Carson, A. Pikalov, and S. Assuncao-Talbott A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy J. Clin. Psychiatry 70 2009 1348 1357
133. J.M. Kane, E. Kim, H.J. Kan, Z. Guo, J.A. Bates, R. Whitehead, and A. Pikalov Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials Appl. Health Econ. Health Policy 7 2009 109 119
134. U.G. Kang, M.S. Seo, M.S. Roh, Y. Kim, S.C. Yoon, and Y.S. Kim The effects of clozapine on the GSK-3-mediated signaling pathway FEBS Lett. 560 2004 115 119 (Pubitemid 38264303)
135. S. Kapur, and P. Seeman Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action J. Psychiatry Neurosci. 25 2000 161 166 (Pubitemid 30233553)
136. S. Kapur, and P. Seeman Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis Am. J. Psychiatry 158 2001 360 369 (Pubitemid 32205190)
137. S. Kapur, R.B. Zipursky, G. Remington, C. Jones, J. DaSilva, A.A. Wilson, and S. Houle 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation Am. J. Psychiatry 155 1998 921 928 (Pubitemid 28307604)
138. D.L. Kelly, R.R. Conley, S. Feldman, Y. Yu, R.P. McMahon, and C.M. Richardson Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia Psychiatr. Q. 77 2006 81 95 (Pubitemid 43060798)
139. A.J. Kim, Y. Shi, R.C. Austin, and G.H. Werstuck Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3 J. Cell Sci. 118 2005 89 99 (Pubitemid 40277107)
140. J.S. Kim, M.Y. Chang, I.T. Yu, J.H. Kim, S.H. Lee, Y.S. Lee, and H. Son Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo J. Neurochem. 89 2004 324 336 (Pubitemid 38495981)
141. W.Y. Kim, S. Kim, and J.H. Kim Chronic microinjection of valproic acid into the nucleus accumbens attenuates amphetamine-induced locomotor activity Neurosci. Lett. 432 2008 54 57
142. S. Koch, K.W. Perry, and F.P. Bymaster Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat Neuropharmacology 46 2004 232 242 (Pubitemid 37532831)
143. V.P. Kontaxakis, P.P. Ferentinos, B.J. Havaki-Kontaxaki, and D.K. Roukas Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review Eur. Psychiatry 20 2005 409 415 (Pubitemid 41318007)
144. K.L. Kopnisky, E. Chalecka-Franaszek, M. Gonzalez-Zulueta, and D.M. Chuang Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities Neuroscience 116 2003 425 435 (Pubitemid 36139913)
145. Y. Kunii, T.M. Hyde, T. Ye, C. Li, B. Kolachana, D. Dickinson, D.R. Weinberger, J.E. Kleinman, and B.K. Lipska Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression Mol. Psychiatry 2013
146. C.H. Lammers, M. Deuschle, H. Weigmann, S. Hartter, C. Hiemke, C. Heese, and I. Heuser Coadministration of clozapine and fluvoxamine in psychotic patients - clinical experience Pharmacopsychiatry 32 1999 76 77 (Pubitemid 29197554)
147. J. Langan, D. Martin, P. Shajahan, and D.J. Smith Antipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series report BMC Psychiatry 12 2012 214
148. N. Legare, C.A. Gregoire, L. De Benedictis, and A. Dumais Increasing the clozapine: Norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy Med. Hypotheses 2013
149. J. Lejeune, I. Larmo, W. Chrzanowski, R. Witte, A. Karavatos, A. Schreiner, A. Lex, and R. Medori Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis Int. Clin. Psychopharmacol. 19 2004 259 269 (Pubitemid 39141942)
150. V. Lerner, B. Chudakova, S. Kravets, and I. Polyakova Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report Clin. Neuropharmacol. 23 2000 284 286 (Pubitemid 32014479)
151. S. Leucht, W. Kissling, and J. McGrath Lithium for schizophrenia Cochrane Database Syst. Rev. 2007 CD003834
152. X. Li, G.N. Bijur, and R.S. Jope Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection Bipolar Disord. 4 2002 137 144 (Pubitemid 34411276)
153. X. Li, and R.S. Jope Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 35 2010 2143 2154
154. X. Li, K.M. Rosborough, A.B. Friedman, W. Zhu, and K.A. Roth Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics Int. J. Neuropsychopharmacol. 10 2007 7 19 (Pubitemid 46122748)
155. J.A. Lieberman, F.P. Bymaster, H.Y. Meltzer, A.Y. Deutch, G.E. Duncan, C.E. Marx, J.R. Aprille, D.S. Dwyer, X.M. Li, S.P. Mahadik, R.S. Duman, J.H. Porter, J.S. Modica-Napolitano, S.S. Newton, and J.G. Csernansky Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection Pharmacol. Rev. 60 2008 358 403
156. C.H. Lin, S.H. Lin, and F.L. Jang Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study J. Clin. Psychopharmacol. 31 2011 563 568
157. M. Lindskog, P. Svenningsson, B.B. Fredholm, P. Greengard, and G. Fisone Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms Neuroscience 88 1999 1005 1008 (Pubitemid 28546983)
158. B.K. Lipska, Z.Z. Khaing, C.S. Weickert, and D.R. Weinberger BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs Eur. J. Neurosci. 14 2001 135 144 (Pubitemid 32738482)
159. W. Loscher Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action Prog. Neurobiol. 58 1999 31 59 (Pubitemid 29166878)
160. W. Loscher Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy CNS Drugs 16 2002 669 694 (Pubitemid 35176853)
161. K. Low, F. Crestani, R. Keist, D. Benke, I. Brunig, J.A. Benson, J.M. Fritschy, T. Rulicke, H. Bluethmann, H. Mohler, and U. Rudolph Molecular and neuronal substrate for the selective attenuation of anxiety Science 290 2000 131 134
162. K.N. Maher, M. Tan, J.W. Tossell, B. Weisinger, P. Gochman, R. Miller, D. Greenstein, G.P. Overman, J.L. Rapoport, and N. Gogtay Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia J. Child Adolesc. Psychopharmacol. 23 2013 110 116
163. L. Mai, R.S. Jope, and X. Li BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents J. Neurochem. 82 2002 75 83 (Pubitemid 34755251)
164. M.E. Maragnoli, F. Fumagalli, M. Gennarelli, G. Racagni, and M.A. Riva Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain Biol. Psychiatry 55 2004 1095 1102 (Pubitemid 38680562)
165. D. Martins-de-Souza, W.F. Gattaz, A. Schmitt, C. Rewerts, G. Maccarrone, E. Dias-Neto, and C.W. Turck Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia Eur. Arch. Psychiatry Clin. Neurosci. 259 2009 151 163
166. B. Masri, A. Salahpour, M. Didriksen, V. Ghisi, J.M. Beaulieu, R.R. Gainetdinov, and M.G. Caron Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics Proc. Natl. Acad. Sci. USA 105 2008 13656 13661
167. J.D. Matthews, C. Siefert, C. Dording, J.W. Denninger, L. Park, A.O. van Nieuwenhuizen, K. Sklarsky, S. Hilliker, C. Homberger, K. Rooney, and M. Fava An open study of aripiprazole and escitalopram for psychotic major depressive disorder J. Clin. Psychopharmacol. 29 2009 73 76
168. M. Mazza, M.R. Squillacioti, R.D. Pecora, L. Janiri, and P. Bria Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial Expert Opin. Pharmacother. 9 2008 3145 3149
169. R.M. McKernan, T.W. Rosahl, D.S. Reynolds, C. Sur, K.A. Wafford, J.R. Atack, S. Farrar, J. Myers, G. Cook, P. Ferris, L. Garrett, L. Bristow, G. Marshall, A. Macaulay, N. Brown, O. Howell, K.W. Moore, R.W. Carling, L.J. Street, J.L. Castro, C.I. Ragan, G.R. Dawson, and P.J. Whiting Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype Nat. Neurosci. 3 2000 587 592 (Pubitemid 30332078)
170. M.C. McLeod, E. Scarr, and B. Dean Effects of benzodiazepine treatment on cortical GABA(A) and muscarinic receptors: studies in schizophrenia and rats Psychiatry Res. 179 2010 139 146
171. M.C. McLeod, S. Sundram, and B. Dean Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain Prog. Neuro-psychopharmacol. Biol. Psychiatry 32 2008 560 567 (Pubitemid 351178976)
172. H.Y. Meltzer, M. Horiguchi, and B.W. Massey The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment Psychopharmacology 213 2011 289 305
173. H.Y. Meltzer, and B.W. Massey The role of serotonin receptors in the action of atypical antipsychotic drugs Curr. Opin. Pharmacol. 11 2011 59 67
174. J.H. Meyer Neurochemical imaging and depressive behaviours Curr. Top. Behav. Neurosci. 14 2013 101 134
175. I.J. Mitchell, A.C. Cooper, M.R. Griffiths, and A.J. Cooper Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat Neuroscience 109 2002 89 99 (Pubitemid 34088149)
176. B. Moghaddam, and D. Javitt From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 37 2012 4 15
177. R. Mojtabai, and M. Olfson National trends in psychotropic medication polypharmacy in office-based psychiatry Arch. Gen. Psychiatry 67 2010 26 36
178. H.J. Moller Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 2003 1101 1111
179. N. Mossaheb, and R.M. Kaufmann Role of aripiprazole in treatment-resistant schizophrenia Neuropsychiatr. Dis. Treat. 8 2012 235 244
180. A. Nadkarni, I. Kalsekar, M. You, R. Forbes, and T. Hebden Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy Clinicoecon. Outcomes Res. 5 2013 49 57
181. J.C. Nelson, and G.I. Papakostas Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials Am. J. Psychiatry 166 2009 980 991
182. J.C. Nelson, M.E. Thase, E.E. Bellocchio, L.M. Rollin, J.M. Eudicone, R.D. McQuade, R.N. Marcus, R.M. Berman, and R.A. Baker Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy Int. Clin. Psychopharmacol. 27 2012 125 133
183. M. Nose, S. Accordini, P. Artioli, F. Barale, C. Barbui, R. Beneduce, D. Berardi, G. Bertolazzi, B. Biancosino, A. Bisogno, R. Bivi, F. Bogetto, M. Boso, A. Bozzani, P. Bucolo, M. Casale, L. Cascone, L. Ciammella, A. Cicolini, G. Cipresso, A. Cipriani, P. Colombo, B. Dal Santo, M. De Francesco, G. Di Lorenzo, W. Di Munzio, G. Ducci, A. Erlicher, E. Esposito, L. Ferrannini, F. Ferrato, A. Ferro, N. Fragomeno, V.F. Parise, M. Frova, F. Gardellin, N. Garzotto, A. Giambartolomei, G. Giupponi, L. Grassi, N. Grazian, L. Grecu, G. Guerrini, F. Laddomada, E. Lazzarin, C. Lintas, F. Malchiodi, L. Malvini, L. Marchiaro, A. Marsilio, M.C. Mauri, A. Mautone, M. Menchetti, G. Migliorini, M. Mollica, D. Moretti, S. Mule, S. Nicholau, F. Nose, G. Occhionero, A.M. Pacilli, S. Pecchioli, M. Percudani, E. Piantato, C. Piazza, F. Pontarollo, R. Pycha, R. Quartesan, L. Rillosi, F. Risso, R. Rizzo, P. Rocca, S. Roma, M. Rossattini, G. Rossi, G. Rossi, A. Sala, C. Santilli, G. Sarao, A. Sarnicola, F. Sartore, S. Scarone, T. Sciarma, A. Siracusano, S. Strizzolo, M. Tansella, G. Targa, A. Tasser, R. Tomasi, R. Travaglini, A. Veronese, and S. Ziero Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia Trials 10 2009 31
184. S. Nykiel, D. Henderson, G. Bhide, and O. Freudenreich Lithium to allow clozapine prescribing in benign ethnic neutropenia Clin. Schizophr. Relat. Psychoses 4 2010 138 140
185. W.T. O'Brien, and P.S. Klein Validating GSK3 as an in vivo target of lithium action Biochem. Soc. Trans. 37 2009 1133 1138
186. G.A. Ordway, and K. Szebeni Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus Int. J. Neuropsychopharmacol. 7 2004 321 327 (Pubitemid 39166466)
187. M.J. Owens, and C.B. Nemeroff Pharmacology of valproate Psychopharmacol. Bull. 37 Suppl 2 2003 17 24
188. R. Pardo, A.G. Andreolotti, B. Ramos, F. Picatoste, and E. Claro Opposed effects of lithium on the MEK-ERK pathway in neural cells: inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms J. Neurochem. 87 2003 417 426 (Pubitemid 37255249)
189. V. Parikh, M.M. Khan, and S.P. Mahadik Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol Neurosci. Lett. 356 2004 135 139 (Pubitemid 38121487)
190. S.W. Park, V.T. Phuong, C.H. Lee, J.G. Lee, M.K. Seo, H.Y. Cho, Z.H. Fang, B.J. Lee, and Y.H. Kim Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress Neurosci. Res. 71 2011 335 340
191. C.J. Phiel, and P.S. Klein Molecular targets of lithium action Annu. Rev. Pharmacol. Toxicol. 41 2001 789 813 (Pubitemid 32385907)
192. F. Pilar-Cuellar, R. Vidal, and A. Pazos Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects Br. J. Pharmacol. 165 2012 1046 1057
193. A. Pillai, A.V. Terry Jr., and S.P. Mahadik Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus Schizophr. Res. 82 2006 95 106 (Pubitemid 43202652)
194. L. Pozzi, K. Hakansson, A. Usiello, A. Borgkvist, M. Lindskog, P. Greengard, and G. Fisone Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum J. Neurochem. 86 2003 451 459 (Pubitemid 36842444)
195. G. Rajkowska Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells Biol. Psychiatry 48 2000 766 777
196. R.P. Rajkumar Functional hallucinations in schizophrenia responding to adjunctive sodium valproate Indian J. Psychol. Med. 34 2012 76 78
197. S. Raskin, R. Durst, G. Katz, and J. Zislin Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia J. Clin. Psychopharmacol. 20 2000 500 503
198. Z. Rogoz Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice Pharmacol. Rep. 62 2010 1191 1196
199. M.S. Roh, T.Y. Eom, A.A. Zmijewska, P. De Sarno, K.A. Roth, and R.S. Jope Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine Biol. Psychiatry 57 2005 278 286 (Pubitemid 40187372)
200. M.S. Roh, M.S. Seo, Y. Kim, S.H. Kim, W.J. Jeon, Y.M. Ahn, U.G. Kang, Y.S. Juhnn, and Y.S. Kim Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex Exp. Mol. Med. 39 2007 353 360 (Pubitemid 47037626)
201. A.J. Rothschild, K.S. Bates, K.L. Boehringer, and A. Syed Olanzapine response in psychotic depression J. Clin. Psychiatry 60 1999 116 118 (Pubitemid 29104388)
202. C. Rummel, W. Kissling, and S. Leucht Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials Schizophr. Res. 80 2005 85 97 (Pubitemid 41587466)
203. W.B. Ruzicka, A. Zhubi, M. Veldic, D.R. Grayson, E. Costa, and A. Guidotti Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection Mol. Psychiatry 12 2007 385 397 (Pubitemid 46496836)
204. W.J. Ryves, and A.J. Harwood Lithium inhibits glycogen synthase kinase-3 by competition for magnesium Biochem. Biophys. Res. Commun. 280 2001 720 725 (Pubitemid 32924489)
205. G. Sachs, K.N. Chengappa, T. Suppes, J.A. Mullen, M. Brecher, N.A. Devine, and D.E. Sweitzer Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study Bipolar Disord. 6 2004 213 223 (Pubitemid 38702297)
206. G.S. Sachs, F. Grossman, S.N. Ghaemi, A. Okamoto, and C.L. Bowden Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety Am. J. Psychiatry 159 2002 1146 1154 (Pubitemid 34743254)
207. M.M. Savic, M.M. Milinkovic, S. Rallapalli, T. Clayton Sr., S. Joksimovic, M. Van Linn, and J.M. Cook The differential role of alpha1- and alpha5-containing GABA(A) receptors in mediating diazepam effects on spontaneous locomotor activity and water-maze learning and memory in rats Int. J. Neuropsychopharmacol. 12 2009 1179 1193
208. H.M. Schipper Heme oxygenase expression in human central nervous system disorders Free Radical Biol. Med. 37 2004 1995 2011 (Pubitemid 39491319)
209. S. Schonfelder, F. Schirmbeck, R. Waltereit, S. Englisch, and M. Zink Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia Clin. Neuropharmacol. 34 2011 256 257
210. C. Schwarz, A. Volz, C. Li, and S. Leucht Valproate for schizophrenia Cochrane Database Syst. Rev. 2008 CD004028
211. A.A. Sepehry, S. Potvin, R. Elie, and E. Stip Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis J. Clin. Psychiatry 68 2007 604 610 (Pubitemid 46663044)
212. R.C. Shelton, G.D. Tollefson, M. Tohen, S. Stahl, K.S. Gannon, T.G. Jacobs, W.R. Buras, F.P. Bymaster, W. Zhang, K.A. Spencer, P.D. Feldman, and H.Y. Meltzer A novel augmentation strategy for treating resistant major depression Am. J. Psychiatry 158 2001 131 134 (Pubitemid 32047260)
213. R.C. Shelton, D.J. Williamson, S.A. Corya, T.M. Sanger, L.E. Van Campen, M. Case, S.D. Briggs, and G.D. Tollefson Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance J. Clin. Psychiatry 66 2005 1289 1297 (Pubitemid 41546509)
214. J.C. Shim, J.G. Shin, D.L. Kelly, D.U. Jung, Y.S. Seo, K.H. Liu, J.H. Shon, and R.R. Conley Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial Am. J. Psychiatry 164 2007 1404 1410 (Pubitemid 47461141)
215. W. Sieghart Structure, pharmacology, and function of GABAA receptor subtypes Adv. Pharmacol. 54 2006 231 263
216. E. Sigel, and M.E. Steinmann Structure, function, and modulation of GABA(A) receptors J. Biol. Chem. 287 2012 40224 40231
217. H. Silver, I. Barash, N. Aharon, A. Kaplan, and M. Poyurovsky Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study Int. Clin. Psychopharmacol. 15 2000 257 261 (Pubitemid 30660960)
218. H. Silver, Y. Chertkow, O. Weinreb, L. Danovich, and M. Youdim Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Neurotherapeutics 6 2009 86 93
219. H. Silver, M. Kushnir, and A. Kaplan Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study Biol. Psychiatry 40 1996 671 674 (Pubitemid 26356403)
220. H. Silver, E. Susser, L. Danovich, W. Bilker, M. Youdim, V. Goldin, and O. Weinreb SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients Int. J. Neuropsychopharmacol. 14 2011 573 584
221. S.P. Singh, V. Singh, N. Kar, and K. Chan Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis Br. J. Psychiatry 197 2010 174 179
222. K.J. Skilbeck, J.N. O'Reilly, G.A. Johnston, and T. Hinton The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined Schizophr. Res. 90 2007 76 80 (Pubitemid 46188518)
223. K.J. Skilbeck, J.N. O'Reilly, G.A. Johnston, and T. Hinton Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites Prog. Neuro-psychopharmacol. Biol. Psychiatry 32 2008 492 498 (Pubitemid 351187833)
224. J.G. Small, M.H. Klapper, F.W. Malloy, and T.M. Steadman Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder J. Clin. Psychopharmacol. 23 2003 223 228 (Pubitemid 36807788)
225. G.L. Snyder, A.A. Fienberg, R.L. Huganir, and P. Greengard A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor J. Neurosci. 18 1998 10297 10303 (Pubitemid 29016549)
226. I.E. Sommer, M.J. Begemann, A. Temmerman, and S. Leucht Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review Schizophr. Bull. 38 2012 1003 1011
227. H. Son, I.T. Yu, S.J. Hwang, J.S. Kim, S.H. Lee, Y.S. Lee, and B.K. Kaang Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus J. Neurochem. 85 2003 872 881 (Pubitemid 36578619)
228. G.I. Spielmans, M.I. Berman, E. Linardatos, N.Z. Rosenlicht, A. Perry, and A.C. Tsai Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes PLoS Med. 10 2013 e1001403
229. E. Spina, P. De Domenico, C. Ruello, N. Longobardo, C. Gitto, M. Ancione, A.E. Di Rosa, and A.P. Caputi Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients Int. Clin. Psychopharmacol. 9 1994 281 285 (Pubitemid 24374889)
230. E. Spina, and J. de Leon Metabolic drug interactions with newer antipsychotics: a comparative review Basic Clin. Pharmacol. Toxicol. 100 2007 4 22 (Pubitemid 46051438)
231. R.F. Squires, A. Lajtha, E. Saederup, and M. Palkovits Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? Neurochem. Res. 18 1993 219 223 (Pubitemid 23067766)
232. S. Stahl, O. Freudenreich, and D. Goff A successful antipsychotic combination trial. Quo Vadis? Acta Psychiatr. Scand. 110 2004 241 242 (Pubitemid 39278981)
233. A.D. Stan, and D.A. Lewis Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies Curr. Pharm. Biotechnol. 13 2012 1557 1562
234. T. Suppes, E. Vieta, S. Liu, M. Brecher, and B. Paulsson Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127) Am. J. Psychiatry 166 2009 476 488
235. T. Suzuki, H. Uchida, K. Watanabe, S. Nakajima, K. Nomura, H. Takeuchi, A. Tanabe, G. Yagi, and H. Kashima Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone Hum. Psychopharmacol. 23 2008 455 463
236. P. Svenningsson, M. Lindskog, C. Ledent, M. Parmentier, P. Greengard, B.B. Fredholm, and G. Fisone Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors Proc. Natl. Acad. Sci. USA 97 2000 1856 1860 (Pubitemid 30118533)
237. P. Svenningsson, A. Nishi, G. Fisone, J.A. Girault, A.C. Nairn, and P. Greengard DARPP-32: an integrator of neurotransmission Annu. Rev. Pharmacol. Toxicol. 44 2004 269 296 (Pubitemid 38263842)
238. P. Svenningsson, E.T. Tzavara, F. Liu, A.A. Fienberg, G.G. Nomikos, and P. Greengard DARPP-32 mediates serotonergic neurotransmission in the forebrain Proc. Natl. Acad. Sci. USA 99 2002 3188 3193 (Pubitemid 34240607)
239. P. Svenningsson, E.T. Tzavara, J.M. Witkin, A.A. Fienberg, G.G. Nomikos, and P. Greengard Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac) Proc. Natl. Acad. Sci. USA 99 2002 3182 3187 (Pubitemid 34240606)
240. N.R. Swerdlow, V. Bakshi, and M.A. Geyer Seroquel restores sensorimotor gating in phencyclidine-treated rats J. Pharmacol. Exp. Ther. 279 1996 1290 1299 (Pubitemid 27166777)
241. N.R. Swerdlow, V. Bakshi, M. Waikar, N. Taaid, and M.A. Geyer Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats Psychopharmacology 140 1998 75 80 (Pubitemid 28524310)
242. D.M. Taylor, L. Smith, S.H. Gee, and J. Nielsen Augmentation of clozapine with a second antipsychotic - a meta-analysis Acta Psychiatr. Scand. 125 2012 15 24
243. M.E. Thase, S.A. Corya, O. Osuntokun, M. Case, D.B. Henley, T.M. Sanger, S.B. Watson, and S. Dube A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder J. Clin. Psychiatry 68 2007 224 236 (Pubitemid 46362643)
244. M. Tohen, K.N. Chengappa, T. Suppes, C.A. Zarate Jr., J.R. Calabrese, C.L. Bowden, G.S. Sachs, D.J. Kupfer, R.W. Baker, R.C. Risser, E.L. Keeter, P.D. Feldman, G.D. Tollefson, and A. Breier Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy Arch. Gen. Psychiatry 59 2002 62 69 (Pubitemid 34044408)
245. C. Tomasetti, C. Dell'Aversano, F. Iasevoli, and A. de Bartolomeis Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action Neuroscience 150 2007 144 158 (Pubitemid 350198687)
246. C. Tomasetti, C. Dell'Aversano, F. Iasevoli, F. Marmo, and A. de Bartolomeis The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes Prog. Neuro-psychopharmacol. Biol. Psychiatry 35 2011 184 197
247. L. Tremolizzo, M.S. Doueiri, E. Dong, D.R. Grayson, J. Davis, G. Pinna, P. Tueting, V. Rodriguez-Menendez, E. Costa, and A. Guidotti Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice Biol. Psychiatry 57 2005 500 509 (Pubitemid 40311985)
248. M.L. Trincavelli, E. Da Pozzo, S. Daniele, and C. Martini The GABAA-BZR complex as target for the development of anxiolytic drugs Curr. Top. Med. Chem. 12 2012 254 269
249. K. Umeda, K. Suemaru, N. Todo, N. Egashira, K. Mishima, K. Iwasaki, M. Fujiwara, and H. Araki Effects of mood stabilizers on the disruption of prepulse inhibition induced by apomorphine or dizocilpine in mice Eur. J. Pharmacol. 553 2006 157 162 (Pubitemid 44779598)
250. G.S. Ungvari, H.F. Chiu, L.Y. Chow, B.S. Lau, and W.K. Tang Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study Psychopharmacology 142 1999 393 398 (Pubitemid 29187628)
251. J.D. Urban, G.A. Vargas, M. von Zastrow, and R.B. Mailman Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 32 2007 67 77 (Pubitemid 44967785)
252. M. Valenstein, J.F. McCarthy, K.L. Austin, J.F. Greden, E.A. Young, and F.C. Blow What happened to lithium? Antidepressant augmentation in clinical settings Am. J. Psychiatry 163 2006 1219 1225 (Pubitemid 44464450)
253. E. Valjent, C. Pages, D. Herve, J.A. Girault, and J. Caboche Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain Eur. J. Neurosci. 19 2004 1826 1836 (Pubitemid 38482570)
254. M. Veldic, B. Kadriu, E. Maloku, R.C. Agis-Balboa, A. Guidotti, J.M. Davis, and E. Costa Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder Schizophr. Res. 91 2007 51 61
255. V. Villari, T. Frieri, and A. Fagiolini Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms J. Clin. Psychopharmacol. 31 2011 375 376
256. A. Volz, V. Khorsand, D. Gillies, and S. Leucht Benzodiazepines for schizophrenia Cochrane Database Syst. Rev. 2007 CD006391
257. J.P. Vriend, and N.A. Alexiuk Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice Mol. Chem. Neuropathol. 27 1996 307 324 (Pubitemid 26142653)
258. J.C. Walz, B.N. Frey, A.C. Andreazza, K.M. Cereser, A.A. Cacilhas, S.S. Valvassori, J. Quevedo, and F. Kapczinski Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania J. Psychiatr. Res. 42 2008 416 421 (Pubitemid 351253581)
259. J. Wang, I.M. Omori, M. Fenton, and B. Soares Sulpiride augmentation for schizophrenia Cochrane Database Syst. Rev. 2010 CD008125
260. A. Wassef, J. Baker, and L.D. Kochan GABA and schizophrenia: a review of basic science and clinical studies J. Clin. Psychopharmacol. 23 2003 601 640 (Pubitemid 37443192)
261. A.A. Wassef, S.G. Dott, A. Harris, A. Brown, M. O'Boyle, W.J. Meyer 3rd, and R.M. Rose Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia J. Clin. Psychopharmacol. 20 2000 357 361 (Pubitemid 30318366)
262. E. Weiner, R.R. Conley, M.P. Ball, S. Feldman, J.M. Gold, D.L. Kelly, I. Wonodi, R.P. McMahon, and R.W. Buchanan Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 35 2010 2274 2283
263. J.W. Williams Jr., C.D. Mulrow, E. Chiquette, P.H. Noel, C. Aguilar, and J. Cornell A systematic review of newer pharmacotherapies for depression in adults: evidence report summary Ann. Intern. Med. 132 2000 743 756 (Pubitemid 30244176)
264. R.S. Williams, L. Cheng, A.W. Mudge, and A.J. Harwood A common mechanism of action for three mood-stabilizing drugs Nature 417 2002 292 295 (Pubitemid 34534711)
265. B.M. Wright, E.H. Eiland 3rd, and R. Lorenz Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature Pharmacotherapy 33 2013 344 359
266. X. Wu, P.S. Chen, S. Dallas, B. Wilson, M.L. Block, C.C. Wang, H. Kinyamu, N. Lu, X. Gao, Y. Leng, D.M. Chuang, W. Zhang, R.B. Lu, and J.S. Hong Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons Int. J. Neuropsychopharmacol. 11 2008 1123 1134
267. H. Xu, Z. Chen, J. He, S. Haimanot, X. Li, L. Dyck, and X.M. Li Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus Hippocampus 16 2006 551 559 (Pubitemid 43942103)
268. H. Xu, H. Qing, W. Lu, D. Keegan, J.S. Richardson, J. Chlan-Fourney, and X.M. Li Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus Neurosci. Lett. 321 2002 65 68 (Pubitemid 34185500)
269. S. Yasuda, M.H. Liang, Z. Marinova, A. Yahyavi, and D.M. Chuang The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons Mol. Psychiatry 14 2009 51 59
270. N. Yasui-Furukori, T. Kondo, K. Mihara, Y. Inoue, and S. Kaneko Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia Psychopharmacology 171 2004 223 227 (Pubitemid 38134660)
271. J.H. Yoon, M.J. Minzenberg, S. Raouf, M. D'Esposito, and C.S. Carter Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia Biol. Psychiatry 2013
272. C. Young, M.M. Straiko, S.A. Johnson, C. Creeley, and J.W. Olney Ethanol causes and lithium prevents neuroapoptosis and suppression of pERK in the infant mouse brain Neurobiol. Dis. 31 2008 355 360
273. P.X. Yuan, L.D. Huang, Y.M. Jiang, J.S. Gutkind, H.K. Manji, and G. Chen The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth J. Biol. Chem. 276 2001 31674 31683
274. W. Zhang, K.W. Perry, D.T. Wong, B.D. Potts, J. Bao, G.D. Tollefson, and F.P. Bymaster Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex Neuropsychopharmacology: Off. Publ. Am. Coll. Neuropsychopharmacol. 23 2000 250 262 (Pubitemid 30609659)
275. G. Zheng, X. Zhang, Y. Chen, Y. Zhang, W. Luo, and J. Chen Evidence for a role of GABAA receptor in the acute restraint stress-induced enhancement of spatial memory Brain Res. 1181 2007 61 73 (Pubitemid 350050916)
276. M. Zink, A. Kuwilsky, B. Krumm, and H. Dressing Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial J. Psychopharmacol. 23 2009 305 314
277. M. Zink, A. Schmitt, B. May, B. Muller, T. Demirakca, D.F. Braus, and F.A. Henn Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression Schizophr. Res. 66 2004 151 157 (Pubitemid 38041113)
278. R. Zoccali, M.R. Muscatello, C. Cedro, P. Neri, D. La Torre, E. Spina, A.E. Di Rosa, and M. Meduri The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study Int. Clin. Psychopharmacol. 19 2004 71 76 (Pubitemid 38324586)